A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Inclusion Criteria: Healthy Volunteers: * Male and female subjects 18 to 55 years of age, inclusive. * Subject is judged to be in good general health. Rheumatoid Arthritis Patients: * Male and female patients 18 to 75 years of age, inclusive. * Subject has a diagnosis of rheumatoid arthritis for at least six months. * Subject has been on methotrexate therapy for at least three months and on a stable dose for at least four weeks. Exclusion Criteria: * History or evidence of active or latent tuberculosis. * History or significant allergic reaction to any drug. * Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or within 5 half-lives of the respective medication, whichever is longer. * Current or expected need for oral intake of at least 10 mg prednisone per day or equivalent corticosteroid therapy. * History of acute inflammatory joint disease of different origin other than rheumatoid arthritis (rheumatoid arthritis patients).